2009 best financial year yet for leading CRO, ClinTec International

Published March 16th, 2010 - 09:31 GMT

 ClinTec International, a leading full service multinational contract research organisation (CRO) that manages clinical trials in all major therapeutic areas, has announced that it has achieved organic growth with a 45 per cent increase in global sales revenues over the last twelve months; expanded its client base and signed new contracts with 11 of the world’s top 25 pharmaceutical firms.


Dr Rabinder Buttar, the company’s founder, president and CEO commented: “ClinTec International is at the top of its growth metrics when compared to competitors. We have met the challenges of 2009 and indeed current projections point to the company’s growth in 2010 and 2011 being sustained to the same high levels.


“Whilst other CROs suffered project delays or cancellations, ClinTec forged ahead developing innovative services in 17 new countries, employing 115 new staff in the process.”


“The launch of our Cairo office in October was one of the high points of the year providing our global pharmaceutical associates with access to new patient populations and cementing our reputation as the major CRO in the Middle East and North Africa (MENA) region,” said Dr Buttar. “ClinTec International excels at opening up new and emerging markets.”


Commenting on the UAE’s role in sharing in the growth of the pharmaceutical industry, Dr Mohammed Abuelkhair, Head, Pharma/Medicine and Medical Products Regulation Section, Health Authority-Abu Dhabi (HAAD) and Chair of PABME Steering and Advisory Board said: “The rate of growth of the pharmaceutical sector in the UAE is likely to strengthen during 2010. While demographic changes will be key drivers of the longer-term growth, the rising demand for treatment in a gradually improving healthcare system will mean that generic products will be the main beneficiaries of this upward trend. The UAE will see two new pharmaceutical factories to begin construction in the immediate future.”


ClinTec has played a key role in 2009 in facilitating complex restructuring programmes for Global Pharma, a pharmaceutical company based in India, who are searching for innovative ways to optimise their R&D efforts. 


In an effort to further boost their presence in the Middle East, ClinTec International will be exhibiting at the PABME Exhibition and Conference, an event organised by IIR Middle East Life Sciences Division, which will run from 23 – 25 May, 2010, at the Dubai International Convention and Exhibition Centre, UAE.


Dr Buttar said: “ClinTec International is continuing to contribute to the success of clinical research in the Middle East and as such we are pleased to continue our strong relationship with PABME in 2010.  ClinTec has consistently developed new markets for clinical research and as such is launching its Academy of Clinical Excellence (ACE).  The Academy will link ClinTec’s established knowledge base in clinical research to local training needs in clinical drug development, which will be appealing to ethics committee’s, regulatory authorities and commercial pharmaceutical companies operating in the region.  Through active participation of ClinTec clinical experts in PABME 2010, we hope to build new relationships, as well as enhance our existing ones and discuss industry issues and opportunities.”

© 2000 - 2019 Al Bawaba (www.albawaba.com)

You may also like